Acute Lymphocytic Leukemia (ALL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Acute Lymphocytic Leukemia (ALL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global ALL market. The report identifies the key trends shaping and driving the global ALL market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ALL sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates the major markets (the US, the UK, Italy, Spain, France, Germany and Japan) for acute lymphocytic leukemia (ALL) therapeutics was valued at $427.6m in 2010 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 2.9% to reach $524.0m by 2017. This growth is primarily attributed to the expected launch of Phase III pipeline candidates Marqibo (vincristine sulfate liposomes injection), GRASPA (asparaginase loaded into erythrocytes), recombinant asparaginase (asparaginase) and Depocyt (liposomal cytarabine) during the forecast period. The moderate growth rate is primarily attributed to the patent expiry of Gleevec in 2015 in the US; 2016 in Europe, Clolar in 2015 in Europe and Arranon in 2017 in US; 2013 in Europe.

Scope

The report provides information on the key drivers and challenges of the acute lymphocytic leukemia market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) ALL therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as tyrosine kinase inhibitor, DNA polymerase inhibitor, histone deacetylase (HDAC) inhibitor, dihydrofolate reductase inhibitor and Eg5 Inhibitor.
• Analysis of the current and future competition in the seven key countries ALL therapeutics market. Key market players covered are Talon Therapeutics, Inc., Pfizer Inc, Genzyme Corporation, Erytech Pharma and Micromet, Inc.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ALL therapeutics market.
• Analysis of key recent licensing and partnership agreements in ALL therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global ALL therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global acute lymphocytic leukemia market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global ALL therapeutics market landscape? - Identify, understand and capitalize.

Table of Contents

1 Table of contents
1.1 List of Tables
1.2 List of Figures

2 Acute Lymphocytic Leukemia (ALL) Therapeutics - Introduction
2.1 Overview
2.1.1 Classification
2.1.2 Variant Features of ALL
2.2 Etiology
2.3 Pathophysiology
2.4 Epidemiology
2.5 Signs and Symptoms
2.6 Prognosis
2.7 Diagnosis
2.8 Treatment and Management Pattern
2.9 GlobalData Pipeline Report Guidance

3 Acute Lymphocytic Leukemia (ALL) Therapeutics - Market Characterization
3.1 ALL Therapeutics Market Size (2005-2010) - Major Markets
3.2 ALL Therapeutics Market Forecast (2010-2017) - Major Markets
3.3 ALL Therapeutics Market Size (2005-2010) - The US
3.4 ALL Therapeutics Market Forecast (2010-2017) - The US
3.5 ALL Therapeutics Market Size (2005-2010) - France
3.6 ALL Therapeutics Market Forecast (2010-2017) - France
3.7 ALL Therapeutics Market Size (2005-2010) - Germany
3.8 ALL Therapeutics Market Forecast (2010-2017) - Germany
3.9 ALL Therapeutics Market Size (2005-2010) - Italy
3.10 ALL Therapeutics Market Forecast (2010-2017) - Italy
3.11 ALL Therapeutics Market Size (2005-2010) - Spain
3.12 ALL Therapeutics Market Forecast (2010-2017) - Spain
3.13 ALL Therapeutics Market Size (2005-2010) - The UK
3.14 ALL Therapeutics Market Forecast (2010-2017) - The UK
3.15 ALL Therapeutics Market Size (2005-2010) - Japan
3.16 ALL Therapeutics Market Forecast (2010-2017) - Japan
3.17 Drivers and Barriers for ALL Therapeutic Market
3.17.1 Drivers for ALL Market
3.17.2 Barriers for Acute Lymphocytic Leukemia Market
3.18 Opportunity and Unmet Need
3.19 Key Takeaway

4 Acute Lymphocytic Leukemia (ALL) Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Acute Lymphocytic Leukemia Market - Marketed Products Profile
4.3.1 Gleevec (imatinib mesylate)
4.3.2 Sprycel (dasatinib)
4.3.3 Oncaspar (pegaspargase)
4.3.4 Clolar (clofarabine)
4.3.5 Arranon (nelarabine)
4.4 Key Takeaway

5 Acute Lymphocytic Leukemia (ALL) Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 ALL Pipeline Analysis - Pipeline by Clinical Phases of Development
5.3.1 ALL Therapeutics - Phase III Clinical Pipeline
5.3.2 ALL Therapeutics - Phase II Clinical Pipeline
5.3.3 ALL Therapeutics - Phase I Clinical Pipeline
5.3.4 ALL Therapeutics - Preclinical Pipeline
5.4 ALL Pipeline by Mechanism of Action
5.5 ALL Therapeutics, Other Promising MOA
5.6 ALL Technology Trends Analytical Framework
5.7 ALL Therapeutics - Promising Drugs under Clinical Development
5.8 Molecule Profile for Promising Drugs Under Clinical Development
5.8.1 GRASPA (L-asparaginase)
5.9 Key Takeaway

6 Acute Lymphocytic Leukemia (ALL) Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials Mapping by Region/Country
6.2 Clinical Trials Mapping by Phase
6.3 Clinical Trials Mapping by Trial Status
6.4 Clinical Trials Mapping by Sponsors
6.5 Clinical Trials Mapping by Prominent Sponsors
6.6 Participants in Therapeutic Clinical Trials - Companies

7 Acute Lymphocytic Leukemia (ALL) Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Acute Lymphocytic Leukemia Therapeutics: Implications for Future Market Competition

8 Acute Lymphocytic Leukemia (ALL) Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Erytech Pharma
8.2.2 Talon Therapeutics Inc.

9 Acute Lymphocytic Leukemia (ALL) Therapeutics - Licensing & Partnership Deals

10 Acute Lymphocytic Leukemia (ALL) Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables

Table 1: ALL Therapeutics - FAB Classification
Table 2: ALL Therapeutics, Incidence Rate by Age, 2007
Table 3: ALL Therapeutics, Incidence Rates by Race
Table 4: ALL Therapeutics, Treatment: Targeted Chemotherapy
Table 5: Acute Lymphocytic Leukemia Therpeutics,Treatment: CALGB 8811 regimen
Table 6: ALL Therapeutics Market, Major Markets, Revenue ($m), 2005-2010
Table 7: ALL Therapeutics Market, Major Markets, Forecast ($m), 2010-2017
Table 8: ALL Therapeutics Market, The US, Revenue ($m), 2005-2010
Table 9: ALL Therapeutics Market, The US, Forecast ($m), 2010-2017
Table 10: ALL Therapeutics Market, France, Revenue ($m), 2005-2010
Table 11: ALL Therapeutics Market, France, Forecast ($m), 2010-2017
Table 12: ALL Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 13: ALL Therapeutics Market, Germany, Forecast ($m), 2010-2017
Table 14: ALL Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 15: ALL Therapeutics Market, Italy, Forecast ($m), 2010-2017
Table 16: ALL Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 17: ALL Therapeutics Market, Spain, Forecast ($m), 2010-2017
Table 18: ALL Therapeutics Market, The UK, Revenue ($m), 2005-2010
Table 19: ALL Therapeutics Market, The UK, Forecast ($m), 2010-2017
Table 20: ALL Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 21: ALL Therapeutics Market, Japan, Forecast ($m), 2010-2017
Table 22: ALL Therapeutics - Phase III Clinical Pipeline
Table 23: ALL Therapeutics - Phase II Clinical Pipeline
Table 24: ALL Therapeutics - Phase I Clinical Pipeline
Table 25: ALL Therapeutics - Preclinical Pipeline
Table 26: ALL Therapeutics, Other Promising Mechanisms of Action
Table 27: ALL Therapeutics - Promising Drugs Under Clinical Development, 2011
Table 28: ALL Therapeutics - Clinical Trials by Country, 2011
Table 29: ALL Therapeutics - Clinical Trials by Phase, 2011
Table 30: ALL Therapeutics - Clinical Trials by Trial Status, 2011
Table 31: ALL Therapeutics - Clinical Trials by Sponsors, 2011
Table 32: ALL Therapeutics - Clinical Trials by Prominent Sponsors, 2011
Table 33: ALL Therapeutics - Companies Participating in Therapeutics Clinical Trials, 2011
Table 34: ERYtech Pharma, Oncology Pipeline, 2011
Table 35: ERYtech Pharma, ALL Pipeline
Table 36: ERYtech Pharma Deals, 2010-11
Table 37: Talon Therapeutics Inc., Oncology Pipeline
Table 38: Talon Therapeutics Inc., ALL Pipeline
Table 39: Talon Therapeutics Inc. Deals, 2010-11
Table 40: ALL Therapeutics, Global, Deals, 2011

1.2 List of Figures

Figure 1: ALL Therapeutics - Hematopoesis
Figure 2: ALL Therapeutics, Bone Aspiration Procedure
Figure 3: ALL Therapeutics, Diagnostic Spinal Tap Test
Figure 4: ALL Therapeutics Market, Major Markets, Revenue ($m), 2005-2010
Figure 5: ALL Therapeutics Market, Major Markets, Forecast ($m), 2010-2017
Figure 6: ALL Therapeutics Market, The US, Revenue ($m), 2005-2010
Figure 7: ALL Therapeutics Market, The US, Forecast ($m), 2010-2017
Figure 8: ALL Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 9: ALL Therapeutics Market, France, Forecast ($m), 2010-2017
Figure 10: ALL Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 11: ALL Therapeutics Market, Germany, Forecast ($m), 2010-2017
Figure 12: ALL Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 13: ALL Therapeutics Market, Italy, Forecast ($m), 2010-2017
Figure 14: ALL Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 15: ALL Therapeutics Market, Spain, Forecast ($m), 2010-2017
Figure 16: ALL Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 17: ALL Therapeutics Market, The UK, Forecast ($m), 2010-2017
Figure 18: ALL Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 19: ALL Therapeutics Market, Japan, Forecast ($m), 2010-2017
Figure 20: ALL Therapeutics, Relapsed Ph+ ALL, Opportunity and Unmet Need, 2011
Figure 21: ALL Therapeutics, Relapsed T-cell ALL, Opportunity and Unmet Need, 2011
Figure 22: ALL Therapeutics - Relapsed Ph+, ALL Strategic Competitor Assessment, 2011
Figure 23: ALL Therapeutics - Relapsed T-cell ALL, Strategic Competitor Assessment, 2011
Figure 24: ALL Therapeutics - Pipeline by Phase of Clinical Development, 2011
Figure 25: ALL Therapeutics - Clinical Pipeline by Mechanism Of Action
Figure 26: ALL Therapeutics, Technology Trends Analytical, 2011
Figure 27: ALL Therapeutics, Technology Trends Analytical Framework - Description, 2011
Figure 28: ALL Therapeutics - Clinical Trials by Country, 2011
Figure 29: ALL Therapeutics - Clinical Trials by Phase, 2011
Figure 30: ALL Therapeutics - Clinical Trials by Trial Status, 2011
Figure 31: ALL Therapeutics - Clinical Trials by Sponsors, 2011
Figure 32: ALL Therapeutics - Clinical Trials by Sponsors, 2011
Figure 33: ALL Therapeutics - Companies Participating in Therapeutics Clinical Trials, 2011
Figure 34: ALL Therapeutics, Key Events Impacting Future Market
Figure 35: ALL Therapeutics, Strategic Assessment, 2011
Figure 36: ALL Therapeutics, Clinical Pipeline by Company, 2011
Figure 37: GlobalData Market Forecasting Model